In this MedCity News article, Mike Mencer, Executive Vice President and General Manager, Early Phase, explains why deploying a robust continuous improvement methodology is especially beneficial in the earliest phases of drug development – ensuring the delivery of high-quality, reliable, timely bioanalytical and clinical data to make informed decisions about either moving on to the next drug development milestone or pivoting to another strategy.
Read the full article here.
